Clinical Trials Search at Vanderbilt-Ingram Cancer Center
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Multiple Cancer Types
This open-label, exploratory study is designed to evaluate the safety and efficacy of
targeted therapies or immunotherapy as single agents or combinations, in participants with
metastatic colorectal cancer (mCRC) whose tumors are biomarker positive as per treatment
arm-specific definition. Eligible participants with mCRC will be enrolled into specific
treatment arms based on their biomarker assay results.
targeted therapies or immunotherapy as single agents or combinations, in participants with
metastatic colorectal cancer (mCRC) whose tumors are biomarker positive as per treatment
arm-specific definition. Eligible participants with mCRC will be enrolled into specific
treatment arms based on their biomarker assay results.
Colon,
Phase I,
Rectal
I
Ciombor, Kristen
NCT04929223
VICCGIP2158
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
Multiple Cancer Types
This is a multicenter, randomized, open-label, controlled Phase 3 trial of XL092 +
atezolizumab vs regorafenib in subjects with microsatellite stable/microsatellite instability
low (MSS/MSI-low) metastatic colorectal cancer (mCRC) who have progressed during, after or
are intolerant to standard-of-care (SOC) therapy.
atezolizumab vs regorafenib in subjects with microsatellite stable/microsatellite instability
low (MSS/MSI-low) metastatic colorectal cancer (mCRC) who have progressed during, after or
are intolerant to standard-of-care (SOC) therapy.
Colon,
Rectal
III
Eng, Cathy
NCT05425940
VICC-DTGIT23267